

Gregory Piazza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3219978/publications.pdf>

Version: 2024-02-01

140
papers

9,058
citations

66315

42
h-index

42364

92
g-index

140
all docs

140
docs citations

140
times ranked

11929
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
2	A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1382-1392.	1.1	648
3	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	3.8	515
4	A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1401-1410.	1.1	280
5	Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 140, e774-e801.	1.6	241
6	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2060-2072.	1.2	230
7	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
8	The Acutely Decompensated Right Ventricle. <i>Chest</i> , 2005, 128, 1836-1852.	0.4	197
9	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	1.2	150
10	Thromboangiitis Obliterans. <i>Circulation</i> , 2010, 121, 1858-1861.	1.6	146
11	Multidisciplinary Pulmonary Embolism Response Teams. <i>Circulation</i> , 2016, 133, 98-103.	1.6	129
12	Acute Pulmonary Embolism. <i>Circulation</i> , 2006, 114, e28-32.	1.6	128
13	Peripheral Artery Disease: Past, Present, and Future. <i>American Journal of Medicine</i> , 2019, 132, 1133-1141.	0.6	123
14	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. <i>American Journal of Medicine</i> , 2016, 129, 1198-1204.	0.6	121
15	Anticoagulation Strategies in Patients With Cancer. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1336-1349.	1.2	121
16	Cerebral Venous Thrombosis. <i>Circulation</i> , 2012, 125, 1704-1709.	1.6	117
17	Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2548.	3.8	117
18	Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1245-1252.	0.7	115

#	ARTICLE	IF	CITATIONS
19	Management of Submassive Pulmonary Embolism. <i>Circulation</i> , 2010, 122, 1124-1129.	1.6	113
20	Fat Embolism Syndrome. <i>Circulation</i> , 2015, 131, 317-320.	1.6	105
21	Venous Thromboembolism and Atherothrombosis An Integrated Approach. <i>Circulation</i> , 2010, 121, 2146-2150.	1.6	99
22	Anticoagulation-associated Adverse Drug Events. <i>American Journal of Medicine</i> , 2011, 124, 1136-1142.	0.6	92
23	Physician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patients. <i>Circulation</i> , 2009, 119, 2196-2201.	1.6	88
24	Double Trouble for 2,609 Hospitalized Medical Patients Who Developed Deep Vein Thrombosis. <i>Chest</i> , 2007, 132, 554-561.	0.4	87
25	Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. <i>JAMA Internal Medicine</i> , 2015, 175, 1112.	2.6	84
26	Diagnosis and Treatment of Lower Extremity Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1765.	3.8	84
27	Venous Thromboembolism in Patients with Diabetes Mellitus. <i>American Journal of Medicine</i> , 2012, 125, 709-716.	0.6	83
28	Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 68-80.	1.0	81
29	Acute Pulmonary Embolism. <i>Circulation</i> , 2006, 114, e42-7.	1.6	80
30	Varicose Veins. <i>Circulation</i> , 2014, 130, 582-587.	1.6	80
31	Update on Guidelines for the Management of Cancer-Associated Thrombosis. <i>Oncologist</i> , 2021, 26, e24-e40.	1.9	76
32	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020, 196, 382-394.	0.8	62
33	Fibrinolysis for acute pulmonary embolism. <i>Vascular Medicine</i> , 2010, 15, 419-428.	0.8	61
34	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. <i>American Heart Journal</i> , 2022, 251, 43-53.	1.2	59
35	Venous thromboembolic events in hospitalised medical patients. <i>Thrombosis and Haemostasis</i> , 2009, 102, 505-510.	1.8	57
36	Mesenteric Venous Thrombosis. <i>Circulation</i> , 2015, 131, 1599-1603.	1.6	56

#	ARTICLE	IF	CITATIONS
37	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141.	1.8	55
38	Warfarin Versus Novel Oral Anticoagulants. <i>Circulation</i> , 2014, 130, e191-3.	1.6	48
39	Advanced Management of Intermediate- and High-Risk Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2117-2127.	1.2	48
40	Pulmonary Embolism in Heart Failure. <i>Circulation</i> , 2008, 118, 1598-1601.	1.6	45
41	Patient Education Program for Venous Thromboembolism Prevention in Hospitalized Patients. <i>American Journal of Medicine</i> , 2012, 125, 258-264.	0.6	45
42	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 408-411.	1.2	44
43	Venous Thromboembolism in Heart Failure: Preventable Deaths During and After Hospitalization. <i>American Journal of Medicine</i> , 2011, 124, 252-259.	0.6	42
44	Submassive Pulmonary Embolism. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 171.	3.8	42
45	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42
46	Computerized Decision Support for the Cardiovascular Clinician. <i>Circulation</i> , 2009, 120, 1133-1137.	1.6	40
47	Heart Failure in Patients With Deep Vein Thrombosis. <i>American Journal of Cardiology</i> , 2008, 101, 1056-1059.	0.7	38
48	Cardiovascular Complications of Novel Multiple Myeloma Treatments. <i>Circulation</i> , 2016, 133, 908-912.	1.6	36
49	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. <i>British Journal of Haematology</i> , 2020, 190, 555-561.	1.2	36
50	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , 2021, 235, 12-23.	1.2	36
51	Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). <i>European Heart Journal</i> , 2020, 41, 1086-1096.	1.0	35
52	Dementia and Atrial Fibrillation: Pathophysiological Mechanisms and Therapeutic Implications. <i>American Journal of Medicine</i> , 2018, 131, 1408-1417.	0.6	34
53	Deep-Vein Thrombosis in the Elderly. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 393-398.	0.7	33
54	Venous Thromboembolism in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Medicine</i> , 2012, 125, 1010-1018.	0.6	33

#	ARTICLE	IF	CITATIONS
55	Venous Thromboembolism and Cancer. <i>Circulation</i> , 2013, 128, 2614-2618.	1.6	33
56	Risk factors for major bleeding in the SEATTLE II trial. <i>Vascular Medicine</i> , 2017, 22, 44-50.	0.8	33
57	Vascular Teams in Peripheral Vascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2477-2486.	1.2	32
58	Venous thromboembolism in patients with symptomatic atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1095-1102.	1.8	26
59	Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962094367.	0.7	26
60	Randomized Trial of Physician Alerts for Thromboprophylaxis after Discharge. <i>American Journal of Medicine</i> , 2013, 126, 435-442.	0.6	25
61	An Original Risk Score to Predict Early Major Bleeding in Acute Pulmonary Embolism. <i>Chest</i> , 2021, 160, 1832-1843.	0.4	25
62	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
63	Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?. <i>Vascular Medicine</i> , 2018, 23, 388-399.	0.8	24
64	The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents. <i>TH Open</i> , 2020, 04, e288-e299.	0.7	23
65	One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009012.	1.4	23
66	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. <i>Blood Advances</i> , 2022, 6, 2967-2976.	2.5	23
67	Evaluation of a Device Combining an Inferior Vena Cava Filter and a Central Venous Catheter for Preventing Pulmonary Embolism Among Critically Ill Trauma Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1248-1254.	0.2	22
68	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22
69	Let's Stop Dichotomizing Venous Thromboembolism as Provoked or Unprovoked. <i>Circulation</i> , 2018, 138, 2591-2593.	1.6	22
70	Implementation of a Comprehensive Post-Discharge Venous Thromboembolism Prophylaxis Program for Abdominal and Pelvic Surgery Patients. <i>Journal of the American College of Surgeons</i> , 2016, 223, 804-813.	0.2	21
71	Running thin: implications of a heparin shortage. <i>Lancet, The</i> , 2020, 395, 534-536.	6.3	20
72	Surgical Pulmonary Embolectomy. <i>Circulation</i> , 2015, 132, 1146-1151.	1.6	18

#	ARTICLE	IF	CITATIONS
73	Surgical pulmonary embolectomy and catheter-directed thrombolysis for treatment of submassive pulmonary embolism. <i>Journal of Cardiac Surgery</i> , 2018, 33, 252-259.	0.3	18
74	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.	0.6	18
75	Improving Clinical Effectiveness in Thromboprophylaxis for Hospitalized Medical Patients. <i>American Journal of Medicine</i> , 2009, 122, 230-232.	0.6	17
76	Thrombophilia Testing, Recurrent Thrombosis, and Women's Health. <i>Circulation</i> , 2014, 130, 283-287.	1.6	17
77	Andexanet Alfa (Andexxa) Formulary Review. <i>Critical Pathways in Cardiology</i> , 2019, 18, 66-71.	0.2	17
78	Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry. <i>Human Reproduction</i> , 2021, 36, 2083-2090.	0.4	17
79	Venous Thromboembolism in Hospitalized Patients With Active Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 469-475.	0.7	16
80	Beyond Virchow's Triad: Does cardiovascular inflammation explain the recurrent nature of venous thromboembolism?. <i>Vascular Medicine</i> , 2015, 20, 102-104.	0.8	16
81	Physician alerts to prevent venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 1-6.	1.0	15
82	Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. <i>Vascular Medicine</i> , 2016, 21, 361-368.	0.8	15
83	First-in-Human Study to Assess the Safety and Feasibility of the Bashir Endovascular Catheter for the Treatment of Acute Intermediate-Risk Pulmonary Embolism. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009611.	1.4	15
84	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15
85	Association of ABO blood group type with cardiovascular events in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 584-586.	1.0	14
86	Quantification and Significance of Pulmonary Vascular Volume in Predicting Response to Ultrasound-Facilitated, Catheter-Directed Fibrinolysis in Acute Pulmonary Embolism (SEATTLE-3D). <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009903.	1.3	13
87	Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 805-814.	1.8	13
88	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	1.9	13
89	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	1.5	13
90	The evidence supporting treatment of reflux and obstruction in chronic venous disease. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 399-412.	0.9	11

#	ARTICLE	IF	CITATIONS
91	A midterm report card for pulmonary embolism response teams. <i>Vascular Medicine</i> , 2018, 23, 72-74.	0.8	11
92	Optimal reperfusion strategy in acute high-risk pulmonary embolism requiring extracorporeal membrane oxygenation support: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2022, 60, 2102977.	3.1	11
93	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. <i>JAMA Network Open</i> , 2022, 5, e2215580.	2.8	11
94	Thrombophilia, Inflammation, and Recurrent Pregnancy Loss: A Case-Based Review. <i>Seminars in Reproductive Medicine</i> , 2021, 39, 062-068.	0.5	10
95	Periprocedural Management of the Chronically Anticoagulated Patient. <i>Critical Pathways in Cardiology</i> , 2003, 2, 96-103.	0.2	9
96	Oh Heavy Burden: Recognizing the Risk of Venous Thromboembolism in Women Undergoing Assisted Reproduction. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2011-2013.	1.8	9
97	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012347.	1.3	9
98	Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 766-776.	1.0	9
99	Predictors of Treatment Response Following Ultrasound-Facilitated Catheter-Directed Thrombolysis for Submassive and Massive Pulmonary Embolism. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008747.	1.4	8
100	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. <i>TH Open</i> , 2018, 02, e33-e38.	0.7	7
101	Venous Thromboembolism in Patients With Prior Stroke. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 43-49.	0.7	6
102	Computed tomography angiography with pulmonary artery thrombus burden and right-to-left ventricular diameter ratio after pulmonary embolism. <i>Vascular</i> , 2017, 25, 54-62.	0.4	6
103	Risk Stratification Model: Lower-Extremity Ultrasonography for Hospitalized Patients with Suspected Deep Vein Thrombosis. <i>Journal of General Internal Medicine</i> , 2018, 33, 21-25.	1.3	6
104	Great Debates in Vascular Medicine: Extended duration anticoagulation for unprovoked venous thromboembolism “Coming to consensus when the debate rages on. <i>Vascular Medicine</i> , 2018, 23, 384-387.	0.8	6
105	Venous Thromboembolism Guidebook. <i>Critical Pathways in Cardiology</i> , 2006, 5, 211-227.	0.2	5
106	Catheter-directed, ultrasound-facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 257-263.	1.0	5
107	Predictors of Not Initiating Anticoagulation After Incident Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2020, 133, 463-472.e5.	0.6	5
108	Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. <i>American Journal of Cardiology</i> , 2020, 133, 175-178.	0.7	4

#	ARTICLE	IF	CITATIONS
109	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1061-1070.	1.8	4
110	A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis. <i>Journal of Visualized Experiments</i> , 2015, , e52761.	0.2	3
111	Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in elderly patients with pulmonary embolism: A SEATTLE II sub-analysis. <i>Vascular Medicine</i> , 2017, 22, 324-330.	0.8	3
112	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 54-61.	0.6	3
113	Collaborative Cardiology and Pulmonary Management of Pulmonary Hypertension. <i>Chest</i> , 2019, 156, 200-202.	0.4	3
114	Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 331-335.	1.0	3
115	Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 201-208.	0.6	3
116	Thrombophilia, Antithrombotic Therapy, and Recurrent Pregnancy Loss: A Call for Pragmatism in the Face of Unknowns. <i>Seminars in Reproductive Medicine</i> , 2021, 39, 167-169.	0.5	3
117	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	0.8	3
118	Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.	0.8	3
119	Antiplatelet Prescription in Atrial Fibrillation: Association with a Low Rate of Anticoagulation. <i>TH Open</i> , 2018, 02, e229-e232.	0.7	2
120	Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities. <i>European Heart Journal</i> , 2019, 40, 1515-1517.	1.0	2
121	Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 281-290.	1.0	2
122	Listen to Your Heart (but DONâ€™T Look at Theirs): Risk Assessment for Home Treatment of Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 20-21.	2.5	2
123	Impact of Atrial Fibrillation on In-Hospital Mortality and Stroke in Acute Aortic Syndromes. <i>American Journal of Medicine</i> , 2021, 134, 1419-1423.	0.6	2
124	Off the beaten path: the need for innovation in medical therapy to improve outcomes in acute pulmonary embolism. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 10-12.	0.4	2
125	Right Ventricular Recovery: Early and Late Changes after Acute PE Diagnosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 797-808.	1.5	2
126	Thrombophilia and Hypercoagulability. <i>Circulation</i> , 2014, 130, e9-10.	1.6	1

#	ARTICLE	IF	CITATIONS
127	Varicose Veins. <i>Circulation</i> , 2014, 130, e59-61.	1.6	1
128	A fortune teller's dream or clinician's nightmare: Right ventricular assessment for risk prediction in pulmonary embolism. <i>Thrombosis Research</i> , 2020, 195, 169-170.	0.8	1
129	Stroke risk factors and outcomes among hospitalized women with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1023-1031.	1.0	1
130	Stability of Alteplase for Catheter-Directed, Ultrasound-Facilitated Thrombolysis. <i>Blood Advances</i> , 2021, 5, 5283-5289.	2.5	1
131	Abstract 11603: Pulmonary Artery Dilation in Submassive Acute Pulmonary Embolus and Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2021, 144, .	1.6	1
132	An Unusual Explanation for Episodic Dyspnea. <i>Circulation</i> , 2006, 114, e485-6.	1.6	0
133	A Diagnosis in Vein. <i>American Journal of Medicine</i> , 2010, 123, 701-703.	0.6	0
134	A case of Horner's syndrome after catheter-based fibrinolysis for pulmonary embolism. <i>Vascular Medicine</i> , 2018, 23, 489-490.	0.8	0
135	Heparin-Induced Thrombocytopenia in Healthy Individuals with Continuous Heparin Infusion. <i>TH Open</i> , 2018, 02, e49-e53.	0.7	0
136	Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 118-126.	0.6	0
137	Trailblazing in pulmonary embolism research: the importance of extending beyond randomized controlled trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 237-239.	0.4	0
138	Images in Vascular Medicine: Pulmonary embolism and acute aortic syndromes "Double trouble when vascular medicine emergencies meet. <i>Vascular Medicine</i> , 2021, , 1358863X2110296.	0.8	0
139	Reply: The pathway to the "truth" in the study of recurrent pregnancy loss and thrombophilia. <i>Human Reproduction</i> , 2021, 37, 191-193.	0.4	0
140	Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. <i>TH Open</i> , 2020, 04, e344-e350.	0.7	0